Molecular Basis for Therapy of AIDS-Defining Cancers [electronic resource] / edited by Dirk P. Dittmer, Susan E. Krown.

Call Number
614.5999
Title
Molecular Basis for Therapy of AIDS-Defining Cancers edited by Dirk P. Dittmer, Susan E. Krown.
Physical Description
XIII, 256 p. online resource.
Contents
The Epidemiology of Cancer in People with HIV -- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies -- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi -- Immunology of HIV-Associated Kaposi Sarcoma -- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma -- Role of NF-?B Inhibitors in HIV-Related Malignancies -- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors -- Viral Interleukin-6: Molecular Biology and Pathogenesis -- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies -- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies -- Interferon in Kaposi’s Sarcoma Biology and Therapy -- Metronomic Therapy for HIV-Associated Malignancies -- Targeting EGFR in HPV-Associated Cancer -- Cidofovir Against Human Papillomavirus-Associated Diseases.
Summary
An increased risk for various cancers is a characteristic of people living with HIV infection. Although only three cancers – Kaposi’s sarcoma, high-grade B-cell lymphomas, and invasive cervical cancer – are considered to be "AIDS-defining" conditions, are associated with oncogenic viruses, and occur with increased frequency as immune function declines, other cancer types also occur significantly more frequently in HIV-positive individuals than in the general population, but are not directly associated with clinical progression to AIDS. Notably these "non-AIDS-defining" cancers include virus-associated cancers such as anal cancer, hepatocellular cancer and Hodgkin’s disease, as well as non-virus associated cancers such as lung cancer. Importantly, there are also large worldwide differences in the incidence and behavior of different AIDS-associated cancers. Although effective combination antiretroviral therapy (cART) may be sufficient in some cases to decrease the incidence or beneficially influence the course of some cancers, in other cases it fails to control cancers in people living with HIV/AIDS. Currently, more than a decade after the widespread introduction of cART, and after major advances in the basic understanding of cancer signaling pathways, we have a unique opportunity to revisit the pathobiology, epidemiology and treatment options for malignancies in people living with HIV/AIDS. Molecular Basis for Therapy of AIDS-Defining Cancers provides a primer on the science of cancer in the setting of HIV infection, as well as examples of novel treatment approaches for HIV-associated neoplasia.
Added Author
Dittmer, Dirk P. editor.
Krown, Susan E. editor.
SpringerLink (Online service)
Subject
MEDICINE.
CANCER RESEARCH.
PHARMACOLOGY.
INFECTIOUS DISEASES.
Biomedicine.
Cancer Research.
Pharmacology/Toxicology.
Infectious Diseases.
Multimedia
  • Libraries with this item
Total Ratings: 0
No records found to display.
 
 
 
04216nam a22004935i 4500
001
 
 
vtls001568408
003
 
 
VRT
005
 
 
20170831183200.0
007
 
 
cr nn 008mamaa
008
 
 
170831s2010    xxu|    s    |||| 0|eng d
020
$a 9781441915139 $9 978-1-4419-1513-9
024
7
$a 10.1007/978-1-4419-1513-9 $2 doi
035
$a (DE-He213)978-1-4419-1513-9
039
9
$a 201708311832 $b santha $y 201708311323 $z vjs2012
050
4
$a RC261-271
072
7
$a MJCL $2 bicssc
072
7
$a MED062000 $2 bisacsh
082
0
4
$a 614.5999 $2 23
245
1
0
$a Molecular Basis for Therapy of AIDS-Defining Cancers $h [electronic resource] / $c edited by Dirk P. Dittmer, Susan E. Krown.
264
1
$a New York, NY : $b Springer New York : $b Imprint: Springer, $c 2010.
300
$a XIII, 256 p. $b online resource.
336
$a text $b txt $2 rdacontent
337
$a computer $b c $2 rdamedia
338
$a online resource $b cr $2 rdacarrier
347
$a text file $b PDF $2 rda
505
0
$a The Epidemiology of Cancer in People with HIV -- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies -- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi -- Immunology of HIV-Associated Kaposi Sarcoma -- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma -- Role of NF-?B Inhibitors in HIV-Related Malignancies -- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors -- Viral Interleukin-6: Molecular Biology and Pathogenesis -- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies -- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies -- Interferon in Kaposi’s Sarcoma Biology and Therapy -- Metronomic Therapy for HIV-Associated Malignancies -- Targeting EGFR in HPV-Associated Cancer -- Cidofovir Against Human Papillomavirus-Associated Diseases.
520
$a An increased risk for various cancers is a characteristic of people living with HIV infection. Although only three cancers – Kaposi’s sarcoma, high-grade B-cell lymphomas, and invasive cervical cancer – are considered to be "AIDS-defining" conditions, are associated with oncogenic viruses, and occur with increased frequency as immune function declines, other cancer types also occur significantly more frequently in HIV-positive individuals than in the general population, but are not directly associated with clinical progression to AIDS. Notably these "non-AIDS-defining" cancers include virus-associated cancers such as anal cancer, hepatocellular cancer and Hodgkin’s disease, as well as non-virus associated cancers such as lung cancer. Importantly, there are also large worldwide differences in the incidence and behavior of different AIDS-associated cancers. Although effective combination antiretroviral therapy (cART) may be sufficient in some cases to decrease the incidence or beneficially influence the course of some cancers, in other cases it fails to control cancers in people living with HIV/AIDS. Currently, more than a decade after the widespread introduction of cART, and after major advances in the basic understanding of cancer signaling pathways, we have a unique opportunity to revisit the pathobiology, epidemiology and treatment options for malignancies in people living with HIV/AIDS. Molecular Basis for Therapy of AIDS-Defining Cancers provides a primer on the science of cancer in the setting of HIV infection, as well as examples of novel treatment approaches for HIV-associated neoplasia.
650
0
$a MEDICINE.
650
0
$a CANCER RESEARCH.
650
0
$a PHARMACOLOGY.
650
0
$a INFECTIOUS DISEASES.
650
1
4
$a Biomedicine.
650
2
4
$a Cancer Research.
650
2
4
$a Pharmacology/Toxicology.
650
2
4
$a Infectious Diseases.
700
1
$a Dittmer, Dirk P. $e editor.
700
1
$a Krown, Susan E. $e editor.
710
2
$a SpringerLink (Online service)
773
0
$t Springer eBooks
776
0
8
$i Printed edition: $z 9781441915122
856
4
0
$u http://dx.doi.org/10.1007/978-1-4419-1513-9
912
$a ZDB-2-SBL
950
$a Biomedical and Life Sciences (Springer-11642)
999
$a VIRTUA               
No Reviews to Display
Summary
An increased risk for various cancers is a characteristic of people living with HIV infection. Although only three cancers – Kaposi’s sarcoma, high-grade B-cell lymphomas, and invasive cervical cancer – are considered to be "AIDS-defining" conditions, are associated with oncogenic viruses, and occur with increased frequency as immune function declines, other cancer types also occur significantly more frequently in HIV-positive individuals than in the general population, but are not directly associated with clinical progression to AIDS. Notably these "non-AIDS-defining" cancers include virus-associated cancers such as anal cancer, hepatocellular cancer and Hodgkin’s disease, as well as non-virus associated cancers such as lung cancer. Importantly, there are also large worldwide differences in the incidence and behavior of different AIDS-associated cancers. Although effective combination antiretroviral therapy (cART) may be sufficient in some cases to decrease the incidence or beneficially influence the course of some cancers, in other cases it fails to control cancers in people living with HIV/AIDS. Currently, more than a decade after the widespread introduction of cART, and after major advances in the basic understanding of cancer signaling pathways, we have a unique opportunity to revisit the pathobiology, epidemiology and treatment options for malignancies in people living with HIV/AIDS. Molecular Basis for Therapy of AIDS-Defining Cancers provides a primer on the science of cancer in the setting of HIV infection, as well as examples of novel treatment approaches for HIV-associated neoplasia.
Contents
The Epidemiology of Cancer in People with HIV -- Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies -- HIV-Related Cancer Management in Resource-Limited Settings: A Case Study of Malawi -- Immunology of HIV-Associated Kaposi Sarcoma -- Targeting Signal Transduction Pathways for the Treatment of Kaposi Sarcoma -- Role of NF-?B Inhibitors in HIV-Related Malignancies -- The Molecular Basis of Lytic Induction Therapy in Relation to Gamma herpesvirus (KSHV, EBV)-Associated, AIDS-Related Tumors -- Viral Interleukin-6: Molecular Biology and Pathogenesis -- Targeting the PI3K/Akt/mTOR Pathway in AIDS-Associated Malignancies -- Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies -- Interferon in Kaposi’s Sarcoma Biology and Therapy -- Metronomic Therapy for HIV-Associated Malignancies -- Targeting EGFR in HPV-Associated Cancer -- Cidofovir Against Human Papillomavirus-Associated Diseases.
Subject
MEDICINE.
CANCER RESEARCH.
PHARMACOLOGY.
INFECTIOUS DISEASES.
Biomedicine.
Cancer Research.
Pharmacology/Toxicology.
Infectious Diseases.
Multimedia